GRTS - Gritstone Oncology Inc Stock Price, Fair Value and News

0.65USD-0.01 (-1.52%)Market Closed

Market Summary

USD0.65-0.01

Market Closed

-1.52%

GRTS Stock Price

View Fullscreen

GRTS RSI Chart

GRTS Valuation

Market Cap

70.6M

Price/Earnings (Trailing)

-0.49

Price/Sales (Trailing)

4.51

Price/Free Cashflow

-0.6

GRTS Price/Sales (Trailing)

GRTS Profitability

Return on Equity

-1.0K%

Return on Assets

-105.6%

Free Cashflow Yield

-167.64%

GRTS Fundamentals

GRTS Revenue

Revenue (TTM)

15.6M

Rev. Growth (Yr)

-28.69%

Rev. Growth (Qtr)

-83.22%

GRTS Earnings

Earnings (TTM)

-144.9M

Earnings Growth (Yr)

-18.84%

Earnings Growth (Qtr)

-31.04%

Breaking Down GRTS Revenue

Last 30 days

-7.1%

Last 90 days

-19.7%

Trailing 12 Months

-66.0%

How does GRTS drawdown profile look like?

GRTS Financial Health

Current Ratio

Debt/Equity

2.89

Debt/Cashflow

-2.86

GRTS Investor Care

Shares Dilution (1Y)

22.11%

Diluted EPS (TTM)

-1.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	15.6M	0	0	0
2023	15.2M	11.7M	10.2M	16.3M
2022	15.7M	18.3M	18.7M	19.9M
2021	42.5M	44.8M	46.5M	48.2M
2020	4.3M	3.6M	3.6M	4.0M
2019	2.4M	3.7M	4.6M	4.4M
2018	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Gritstone Oncology Inc

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

CEO	Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
WEBSITE	https://gritstonebio.com
INDUSTRY	Biotechnology
EMPLOYEES	233

Gritstone Oncology Inc Frequently Asked Questions

What is the ticker symbol for Gritstone Oncology Inc? What does GRTS stand for in stocks?

GRTS is the stock ticker symbol of Gritstone Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gritstone Oncology Inc (GRTS)?

As of Fri Jul 26 2024, market cap of Gritstone Oncology Inc is 70.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRTS stock?

You can check GRTS's fair value in chart for subscribers.

Is Gritstone Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether GRTS is over valued or under valued. Whether Gritstone Oncology Inc is cheap or expensive depends on the assumptions which impact Gritstone Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRTS.

What is Gritstone Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, GRTS's PE ratio (Price to Earnings) is -0.49 and Price to Sales (PS) ratio is 4.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GRTS PE ratio will change depending on the future growth rate expectations of investors.